
Southampton
Horizontal Tabs
Treatment Modalities
Surgery
Gene therapy
Immunotherapy
Biologics
Radioimmunotherapy
Medical Devices
Therapeutic vaccines
Small Molecules
Radiotherapy
Chemoradiotherapy
Facilities/Translational Research
Phase 1 Capabilities
- Phase 1 population: both solid and haematological tumours, adult
- Centre specific translational research interest: Our primary expertise to date has been in the development of early phase immunotherapeutics. We are now actively working on developing strategies to control anti-aptoptotic pathways and are developing novel small molecules for clinical testing.
- Multi-centre Phase 1 studies: with a particular interest in immunotherapeutic and anti-apoptotic pathways.
- First-in-Man studies
Mechanisms studied:
- Taxane
- TKI
- HDAC inhibitors
- Diaphorase inhibitor
- Hsp 90 inhibitor
- Vinca alkaloid
- Broad range of novel immunotherapeutics (vaccines, antibodies, adjuvants)
Technology/equipment available within the centre
- Full range of medical imaging: CT, MRI (funding for 3T machine under consideration), CT/PET, Gamma camera
- Wellcome Trust Clinical Research Facility: for the accommodation of patients in early phase studies, including apheresis equipment and sample processing facilities.
- Radiopharmacy: with full MHRA licence for manufacture of immunoconjugates.
- Cellular therapy GMP lab: with full MHRA licence for manufacture and storage.
Sample collection
- Tissue Banking Activity: in-house HTA licenced Tissue Bank for fresh-frozen tissue, single-cell suspension, whole blood, PBMC, serum and plasma.
-
Centre contact responsible for sample collection: Kathleen Potter, Ph.D. Telephone: 02381 205034
Other equipment/ facilities not available on site:
- Mass spectrometry
- Proteomic analysis (university site)
- NMR for structural protein analyses (university site)
- HPLC
ECMC funding provides infrastructure support for early phase and translational research. From the ECMC Southampton portfolio, the following trials have been carried out.
Trial activity between 2012-2015:
Trial by disease type between 2012-2015:
Southampton ECMC has in-house expertise in the design and conduct of early phase clinical trials with immunomodulatory compounds